Dr Ana-Mishel (AM) Spiroski and Ziad Mallat
Dec 18, 2025, 23:22
Dr Ana-Mishel (AM) Spiroski Shares Ziad Mallat’s Article: Translating Nobel Prize-Winning Treg Cell Science Into Cardiovascular Therapy
Dr Ana-Mishel (AM) Spiroski, Cardiovascular TA Lead, Age-Related Diseases TA Lead, Group Leader, In Vivo Pharmacology at Evotec, quoted Ziad Mallat’s post on LinkedIn:
“This is one of the most exciting areas in cardiovascular drug development. A fantastic comment by Professor Zallat Cambridge Cardiovascular on the potential of immune tolerance in cardiovascular therapeutics.”
Quoting Ziad Mallat’s post:
“Here’s the full PDF of the comment published in Nature Cardiovascular Reserach. Translating Nobel Prize-winning Treg cell science into cardiovascular therapy.”
Read full article here.
Follow the latest in Hemostasis Today.
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:18Thomas Dayspring: Prognostic Impact of Lp(a) Changes Following Statin Therapy in Patients with CAD
-
Aug 26, 2026, 14:17Khurram Nasir: Are We Debating the Wrong Thing About Research in Medical Training?
-
Aug 26, 2026, 14:15Nathan Connell: Why Format Free Publishing Still Demands Formatting?
-
Aug 26, 2026, 14:14Reza Shojaei: China’s Reliance on Imported Albumin Raises Global Plasma Security Concerns
-
Aug 26, 2026, 14:03Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM